Shares of Medtronic plc (NYSE:MDT - Get Free Report) traded down 0.3% during trading on Monday . The stock traded as low as $81.92 and last traded at $82.21. 961,526 shares changed hands during mid-day trading, a decline of 85% from the average session volume of 6,216,522 shares. The stock had previously closed at $82.48.
Several equities analysts have commented on the stock. Oppenheimer raised their price target on shares of Medtronic from $92.00 to $94.00 and gave the company a "market perform" rating in a research report on Wednesday, August 21st. Barclays raised their price objective on shares of Medtronic from $105.00 to $109.00 and gave the company an "overweight" rating in a report on Tuesday, November 26th. Needham & Company LLC restated a "hold" rating on shares of Medtronic in a report on Monday, November 18th. Royal Bank of Canada upgraded shares of Medtronic from a "sector perform" rating to an "outperform" rating and raised their price objective for the company from $98.00 to $105.00 in a report on Thursday, October 10th. Finally, Citigroup raised their price objective on shares of Medtronic from $85.00 to $92.00 and gave the company a "neutral" rating in a report on Tuesday, October 1st. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Medtronic presently has a consensus rating of "Hold" and an average target price of $95.27.
Read Our Latest Research Report on MDT
The firm has a market cap of $104.31 billion, a PE ratio of 25.14, a P/E/G ratio of 2.35 and a beta of 0.82. The company's fifty day moving average price is $87.66 and its two-hundred day moving average price is $85.03. The company has a quick ratio of 1.39, a current ratio of 1.84 and a debt-to-equity ratio of 0.51.
Medtronic (NYSE:MDT - Get Free Report) last released its quarterly earnings data on Tuesday, November 19th. The medical technology company reported $1.26 EPS for the quarter, topping analysts' consensus estimates of $1.25 by $0.01. Medtronic had a net margin of 13.00% and a return on equity of 13.79%. The firm had revenue of $8.40 billion for the quarter, compared to the consensus estimate of $8.27 billion. During the same quarter in the previous year, the firm earned $1.25 earnings per share. The firm's revenue was up 5.2% on a year-over-year basis. As a group, sell-side analysts forecast that Medtronic plc will post 5.45 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, January 10th. Shareholders of record on Friday, December 27th will be issued a $0.70 dividend. This represents a $2.80 annualized dividend and a dividend yield of 3.44%. The ex-dividend date of this dividend is Friday, December 27th. Medtronic's dividend payout ratio (DPR) is presently 85.63%.
Institutional investors have recently modified their holdings of the company. Fortitude Family Office LLC acquired a new position in Medtronic during the third quarter worth approximately $27,000. Highline Wealth Partners LLC purchased a new stake in Medtronic during the third quarter worth approximately $27,000. Darwin Wealth Management LLC purchased a new stake in Medtronic during the third quarter worth approximately $27,000. J. Stern & Co. LLP purchased a new stake in Medtronic during the third quarter worth approximately $30,000. Finally, Chelsea Counsel Co. purchased a new stake in Medtronic during the third quarter worth approximately $45,000. Institutional investors and hedge funds own 82.06% of the company's stock.
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Medtronic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medtronic wasn't on the list.
While Medtronic currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.